Leerink Partners

Leerink Partners is a specialized investment bank exclusively focused on the healthcare sector. For three decades, the firm has provided investment banking, equity research, and capital markets services to healthcare companies across biopharma, digital health, medical technology, healthcare services, and tools & diagnostics verticals. The firm recently expanded internationally with a London office.

The firm's investment banking services span M&A advisory, equity offerings (IPOs, follow-ons, PIPEs), convertible notes, and strategic advisory. Recent transactions include a $6.3 billion IPO for Medline, a $550 million follow-on for Vaxcyte, and a $450 million hospital sale advisory for Community Health Systems. The firm has completed transactions totaling billions in capital raised and M&A advisory.

Leerink Partners maintains dedicated teams across five healthcare subsectors, with senior bankers leading engagements from origination through closing. The firm produces equity research and hosts podcasts featuring healthcare industry experts, demonstrating thought leadership in healthcare investment trends and policy.

Choose Leerink Partners when executing significant capital markets transactions or strategic M&A in the healthcare sector where deep industry knowledge impacts valuation and deal success. The firm's exclusive healthcare focus and 30-year track record provide sector credibility and investor relationships that matter for IPOs, large equity raises, or complex M&A advisory.

Expect senior banker involvement throughout the engagement, with teams drawing on extensive healthcare subsector expertise and established relationships with healthcare-focused institutional investors and strategic acquirers. The firm's equity research capabilities and thought leadership provide additional market intelligence to inform transaction strategy and timing.

Leerink Partners operates exclusively in healthcare with dedicated practice groups covering biopharma (biotech and pharmaceutical companies), digital health and health technology, healthcare services (payers, providers, physician practices), medical technology (devices and equipment), and tools & diagnostics. The firm maintains specialized teams for pharma services outsourcing and financial sponsor coverage.

Recent healthcare transactions span multiple subsectors including convertible notes for diagnostics companies, hospital system divestitures, medtech IPOs, and biopharma private placements. The firm produces healthcare-focused equity research and hosts policy-focused podcasts with healthcare experts, demonstrating deep engagement with healthcare industry trends, regulatory developments, and reimbursement dynamics that impact valuations and investment decisions.

Mid-market to large-cap healthcare companies preparing for IPOs, growth equity raises, or strategic M&A transactions; venture-backed digital health and biopharma companies reaching commercialization stages; healthcare services platforms seeking consolidation or exit opportunities; private equity firms making platform acquisitions or portfolio exits in healthcare. Clients typically require transaction values exceeding $100 million where healthcare sector expertise significantly impacts outcomes.